Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Medicine & Life Sciences

1. Glioblastoma 100%
2. Heterografts 66%
3. Organoids 64%
4. Glioma 51%
5. Brain Neoplasms 36%
6. Systems Analysis 34%
7. Neoplasms 31%
8. Precision Medicine 29%
9. RNA Sequence Analysis 27%
10. Clonal Evolution 21%
11. Tumor Microenvironment 20%
12. Temozolomide 16%
13. Therapeutics 16%
14. Gene Expression Profiling 12%
15. Technology 12%
16. DNA Methylation 12%
17. Nervous System Neoplasms 9%
18. Central Nervous System 9%
19. Learning 9%
20. Interdisciplinary Research 9%
21. Direction compound 8%
22. Disease Resistance 8%
23. Private Sector 8%
24. Health Care Sector 8%
25. Systems Biology 7%
26. Radio 6%
27. Adjuvant Chemotherapy 6%
28. Genomics 6%
29. Brain 6%
30. Mutation 6%
31. Standard of Care 6%
32. Blood-Brain Barrier 6%
33. High-Throughput Nucleotide Sequencing 6%
34. Microglia 6%
35. Drug Development 6%
36. Computational Biology 6%
37. Proteomics 6%
38. Methylation 5%
39. Health Care Costs 5%
40. Neuroglia 5%
41. Survivors 5%
42. Pharmaceutical Preparations 5%
43. Disease Progression 5%
44. Clone Cells 5%
45. Datasets 5%
46. Signal Transduction 5%
47. Economics 5%
48. Ecosystem 5%